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chemotherapyAbstract Background: In our previous randomised phase 2 study for patients with
gemcitabine-refractory advanced pancreatic cancer, S-1 plus leucovorin improved
progression-free survival compared with S-1 alone. Here, we evaluated the efficacy of TAS-
118 (S-1 plus leucovorin) versus S-1 in overall survival (OS).
Patients and methods: This randomised, open-label, phase 3 study was conducted at 58 centres
in Japan and Korea. Patients with metastatic pancreatic cancer that progressed during first-
line gemcitabine-based chemotherapy or recurred during or after post-operative gemcita-
bine-based adjuvant treatment were randomly assigned (1:1) to receive either S-1 (40
e60 mg, twice daily for 4 weeks in a 6-week cycle) or TAS-118 (S-1 40e60 mg plus leucovorin
25 mg, twice daily for 1 week in a 2-week cycle). The primary end-point was OS.
Results: A total of 603 patients were randomised, and 300 and 301 patients received TAS-118
and S-1, respectively. There was no difference in OS between groups (median OS for TAS-118
versus S-1, 7.6 months versus 7.9 months; hazard ratio [HR], 0.98 [95% confidence interval
(CI), 0.82e1.16]; P Z 0.756). Progression-free survival was significantly longer with TAS-
118 than S-1 (median, 3.9 months versus 2.8 months; HR, 0.80 [95% CI, 0.67e0.95];
P Z 0.009). There were interactions between Japan and Korea (P Z 0.004) and between un-
resectable and recurrent disease (P Z 0.025) in OS. Incidence, profile and severity of adverse
events were similar between groups.
Conclusion: TAS-118 did not improve OS in patients with gemcitabine-refractory advanced
pancreatic cancer compared to S-1. Further studies are needed to find patients who have
benefit from adding leucovorin to S-1.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gemcitabine monotherapy was the standard first-line
therapy for patients with advanced pancreatic cancer [1]
until gemcitabine plus nab-paclitaxel and FOLFIR-
INOX were developed [2,3]. While these combination
regimens are recommended as the standard first-line
therapy for patients with good performance status
(PS) [4], gemcitabine monotherapy is still used for pa-
tients with advanced pancreatic cancer to avoid severe
toxicities as well as for patients in post-operative adju-
vant settings.
Limited treatment options were available for
gemcitabine-refractory advanced pancreatic cancer,
although two regimens, oxaliplatin with fluorouracil and
folinic acid in CONKO-003 study and nanoliposomal
irinotecan with fluorouracil and folinic acid in
NAPOLI-1 study, recently showed survival benefits
[5,6]. Monotherapy with S-1, an oral fluoropyrimidine
drug comprising tegafur, gimeracil and oteracil potas-
sium, demonstrated non-inferiority to gemcitabine as
first-line therapy for advanced pancreatic cancer, andfavourable results were reported for its use in
gemcitabine-refractory patients [7,8]. Since then, S-1
monotherapy has often been used for patients with
gemcitabine-refractory pancreatic cancer in Japan and
Korea.
Leucovorin enhances the efficacy of fluorouracil by
stabilising the ternary complex with thymidylate syn-
thase, fluorodeoxyuridine monophosphate and 5,10-
methylenetetrahydrofolate, thereby strongly inhibiting
DNA synthesis. S-1 plus leucovorin combination ther-
apy (S-1/LV) has been studied in several clinical trials
for gastrointestinal cancers [9e11] and improved
progression-free survival (PFS) compared with S-1
monotherapy in a randomised phase 2 study for patients
with gemcitabine-refractory advanced pancreatic cancer
[12].
TAS-118 (Taiho Pharmaceutical, Tokyo, Japan) is
an oral combination drug consisting of S-1 and leu-
covorin. In this phase 3 study, we assessed overall
survival (OS) with TAS-118 compared to S-1 in pa-
tients with gemcitabine-refractory advanced pancreatic
cancer.
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2.1. Study design and treatment
This randomised, open-label, multicenter, phase 3 study
was conducted at 58 study sites in Japan and Korea.
Patients were randomly assigned (1:1) to receive either
TAS-118 or S-1 using stratification factors of pancreatic
resection history (), Eastern Cooperative Oncology
Group PS (0/1) and country (Japan/Korea). Key eligi-
bility criteria were histologically or cytologically
confirmed pancreatic adenocarcinoma or adenosqu-
amous carcinoma, refractory to gemcitabine (progression
during first-line gemcitabine-based chemotherapy or
recurrence during or within 6months after post-operative
gemcitabine-based adjuvant chemotherapy), no prior
chemotherapy with fluoropyrimidine, at least one
measurable or evaluable metastatic lesion, age 20e79
years, PS 0e1, serum albumin3.5 g/dL and appropriate
organ function. The study was approved by the institu-
tional review board at each study site and was conducted
in accordance with Good Clinical Practice Guidelines.
All patients provided written informed consent.
S-1 was orally administered twice daily for 4 weeks in
a 6-week cycle. TAS-118, which contains S-1 (30, 40, 50
or 60 mg) and leucovorin (25 mg), was orally adminis-
tered twice daily for 1 week in a 2-week cycle. Initial
doses of S-1 and TAS-118 were determined according to
body surface area (as S-1, 40 mg for patients with body
surface area <1.25 m2; 50 mg for 1.25 to <1.5 m2;
60 mg for 1.5 m2). Patients continued the study
treatment until disease progression, unacceptable
toxicity or consent withdrawal.
During the study treatment, adverse events (AEs)
were evaluated based on the Common Terminology
Criteria for Adverse Events version 4.03 every 2 weeks.
Tumour response was evaluated by the investigators
according to Response Evaluation Criteria in Solid
Tumours version 1.1 every 6 weeks. Survival after
discontinuation of the study was followed every 8 weeks.
2.2. Outcomes
The primary end-point was OS, defined as the time from
randomisation to death due to any cause. The secondary
end-points were safety, PFS (the time from random-
isation to disease progression or death due to any cause,
whichever came first), overall response rate (ORR) and
disease control rate (DCR).
2.3. Statistical analysis
We anticipated median OS in the S-1 group to be 6.0
months for Japanese patients and 4.5 months for
Korean patients [12,13]. To detect a 25% risk reduction
for OS in the TAS-118 group compared to the S-1 group
at a two-sided significance level of 0.05 with 90% power,508 events were required. The planned sample size was
600 patients.
Two interim analyses by the independent data moni-
toring committee were planned to recommend early
termination of this study; the first after 50 deaths to assess
safety, and the second after 100 deaths to assess efficacy.
Upon recommendations from the data monitoring com-
mittee at the two interim analyses, this study was
completed without modification. The primary analysis
used the stratified log-rank test and the Cox proportional
hazards (CPH) model including treatment groups and
stratification factors. A 5% significance level was adjusted
by the O’Brien-Fleming method for multiple testing.
The efficacy was analysed on the full analysis set,
consisting of the patients that met the following criteria:
histologically or cytologically confirmed pancreatic
cancer, refractory to gemcitabine, receiving the study
drug at least once. OS and PFS were analysed by the
KaplaneMeier method. Safety was evaluated in all pa-
tients who received the study treatment at least once.
Before the data cut-off, Z score analysis was addi-
tionally preplanned because patient baseline character-
istics were substantially different between the two
countries under the blinded condition for treatment
groups. Z score was calculated as hazard ratio (HR)
divided by standard error by the CPH model using
stratification factors as covariates and was analysed for
the following patient subgroups: no history of pancre-
atic resection, prior chemotherapy gemcitabine alone,
age <70 years, HbA1c <8.0% and C-reactive protein
(CRP) < 2.0 mg/dL. Z scores of <1.96 imply that
TAS-118 is significantly superior to S-1 with a two-sided
5% significance level.3. Results
3.1. Patients
Between July 2013 and August 2015, 603 patients were
randomised to TAS-118 (nZ 301) or S-1 (nZ 302), and
296 patients in the TAS-118 group and 290 in the S-1
group were included in the full analysis set (Fig. 1).
Baseline characteristics were well balanced between
treatment groups (Table 1). Some differences were
observed between the two countries in age, PS and prior
treatment (Supplementary Table S1). Baseline tumour
burdens (target lesion, tumour diameter, number of
metastatic sites and organs and CA19-9 level) tended to
be larger in patients without pancreatic resection history
than those with resection, especially among Japanese
patients (Supplementary Table S2).3.2. Efficacy
At the data cut-off date (10 May 2016), with a median
follow-up time of 18.0 months, 514 events occurred (260
704 signed informed consent 
603 randomised
301 allocated to TAS-118
300 received TAS-118 (safety population)
1 did not receive TAS-118 
(did not meet criteria for starting cycle 1)
302 allocated to S-1
301 received S-1 (safety population)
1 did not receive S-1 
(needed medicine prohibited by the study)
289 discontinued
249 had progression by RECIST
26 due to adverse events
7 withdrew consent
7 due to investigators’ decision 
11 ongoing at data cutoff
297 discontinued
261 had progression by RECIST
29 due to adverse events
2 withdrew consent
4 due to investigators’ decision
1 had critical protocol deviation
4 ongoing at data cutoff
253 included in TREP
43 excluded from TREP
40 had no target lesions
3 not assessed 
238 included in TREP
52 excluded from TREP
46 had no target lesions
6 not assessed 
101 ineligible
296 included in full analysis set
4 excluded from full analysis set 
(did not meet criteria of GEM failure)
290 included in full analysis set
11 excluded from full analysis set
(did not meet criteria for GEM failure)
Fig. 1. Trial profile. GEM, gemcitabine; RECIST, Response Evaluation Criteria in Solid Tumours (version 1.1); TREP, tumour response-
evaluable population.
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Median OS was 7.6 months (95% confidence interval
[CI], 7.0e8.2) in the TAS-118 group and 7.9 months
(95% CI, 7.0e8.4) in the S-1 group (HR, 0.98 [95% CI,
0.82e1.16]; P Z 0.756; Fig. 2A). PFS was significantly
longer in the TAS-118 group than the S-1 group: 3.9
months (95% CI, 2.8e4.2) versus 2.8 months (95% CI,
2.7e2.9; HR, 0.80 [95% CI, 0.67e0.95]; P Z 0.009;
Fig. 2B). Post-study treatment was performed in 166
(56.1%) and 185 (63.8%) patients from the TAS-118 and
S-1 groups, respectively (Supplementary Table S3).
FOLFIRINOX was given to 24 (8.1%) and 28 (9.7%)
patients, and gemcitabine plus nab-paclitaxel to 33
(11.1%) and 36 (12.4%) patients from the TAS-118 and
S-1 groups, respectively. The proportion of patients with
post-study treatment was smallest (42.6%) in the Korean
TAS-118 group.
Forest plots of OS and PFS are shown in Fig. 3A and
B. Factors favouring TAS-118 (P < 0.1) in terms of OS
and PFS were country (Japan), age (<70 years), baseline
CRP (<2.0 mg/dL) and HbA1c (<8%). The subgroup
analyses of OS and PFS by country are summarised in
Supplementary Tables S4eS5.
The prespecified subgroup analyses of OS and PFS
by country (Japan/Korea) and history of pancreatic
resection () are shown in Fig. 4A and B. Median OS ofJapanese patients was 8.0 months (95% CI, 7.3e9.8) and
7.9 months (95% CI, 7.1e8.5) in the TAS-118 and S-1
groups, respectively (HR, 0.85 [95% CI, 0.70e1.04];
PZ 0.138), while median OS of Korean patients was 6.0
months (95% CI, 5.0e7.0) and 7.4 months (95% CI,
5.4e8.8), respectively (HR, 1.57 [95% CI, 1.07e2.30];
P Z 0.027; Fig. 4A). Median OS of patients without
history of pancreatic resection was 7.3 months (95% CI,
6.4e7.9) and 7.4 months (95% CI, 6.4e8.1) in the TAS-
118 and S-1 groups, respectively (HR, 0.85 [95% CI,
0.70e1.04]; P Z 0.129), while median OS of patients
with history of pancreatic resection was 8.7 months
(95% CI, 7.1e11.2) and 9.4 months (95% CI, 8.1e12.6),
respectively (HR, 1.51 [95% CI, 1.07e2.14]; P Z 0.050;
Fig. 4B). For Japanese patients without pancreatic
resection, both OS and PFS showed trends favouring
TAS-118 (Supplementary Table S6 and Supplementary
Figs. S1a and S1b).
Z scores differed substantially between two countries,
favouringTAS-118 in Japanese patients but S-1 inKorean
patients (Supplementary Fig. S2). In Japanese patients,Z
scores of OS were below the significance limit of1.96 in
any combination of prespecified factors. Z scores of OS
decreased with increasing number of prespecified factors.
In Korean patients, Z scores of OS and PFS were not
correlated with the number of prespecified factors.
Table 1
Baseline characteristics.
Characteristics TAS-118
(n Z 296)
S-1
(n Z 290)
Sex
Male 173 (58.4%) 167 (57.6%)
Female 123 (41.6%) 123 (42.4%)
Age (y)
Median (range) 65 (30e79) 64 (32e79)
Country
Japan 235 (79.4%) 231 (79.7%)
Korea 61 (20.6%) 59 (20.3%)
ECOG performance status
0 169 (57.1%) 161 (55.5%)
1 127 (42.9%) 129 (44.5%)
Site of primary lesion
Head 128 (43.2%) 135 (46.6%)
Other 168 (56.8%) 155 (53.4%)
Pancreatic resection
No 211 (71.3%) 209 (72.1%)
Yes 85 (28.7%) 81 (27.9%)
Measurable lesiona
No 40 (13.5%) 46 (15.9%)
Yes 256 (86.5%) 244 (84.1%)
Number of metastatic sitesb
0 1 (0.3%) 0 (0.0%)
1 136 (45.9%) 117 (40.3%)
2 100 (33.8%) 103 (35.5%)
3 59 (19.9%) 70 (24.1%)
Metastatic site
Liver 194 (65.5%) 185 (63.8%)
Lung 82 (27.7%) 99 (34.1%)
Peritoneum 71 (24.0%) 67 (23.1%)
Previous treatment
Gemcitabine-based chemotherapy 212 (71.6%) 209 (72.1%)
Resection plus gemcitabine-based
chemotherapy
84 (28.4%) 81 (27.9%)
Albumin (g/dL)
Median (range) 4.0 (3.1e4.9) 3.9 (3.1e4.9)
C-reactive protein
<2.0 mg/dL 269 (90.9%) 271 (93.4%)
2.0 mg/dL 27 (9.1%) 19 (6.6%)
Baseline HbA1c
<8% 263 (89.5%) 269 (93.4%)
8% 31 (10.5%) 19 (6.6%)
ECOG, Eastern Cooperative Oncology Group; HbA1c, glycated he-
moglobin; RECIST, Response Evaluation Criteria in Solid Tumours.
Data are n (%), unless otherwise stated.
Analysis set: full analysis set.
a Assessed according to RECIST version 1.1.
b Including target lesions and non-target lesions assessed according
to RECIST version 1.1.
T. Ioka et al. / European Journal of Cancer 106 (2019) 78e8882ORRs were 20.6% and 15.1% (PZ 0.127), and DCRs
were 67.2% and 59.2% (P Z 0.075) in the TAS-118 and
S-1 groups, respectively.
3.3. Safety
Common AEs (10%) are listed in Table 2. The most
common AEs in the TAS-118 group were decreased
appetite (58.0%), stomatitis (50.3%) and diarrhoea
(48.7%), and those in the S-1 group were decreasedappetite (54.8%), diarrhoea (42.5%) and nausea (40.5%).
The numbers of patients who discontinued the study
treatment due to AEs were 26 (8.7%) and 29 (9.6%) in
the TAS-118 and S-1 groups, respectively (Fig. 1). Dose
reduction due to AEs was reported in 108 (36.0%) and
45 (15.0%) patients from the TAS-118 and S-1 groups,
respectively. AEs leading to death were observed in 16
(5.3%) and 12 (4.0%) patients from the TAS-118 and S-1
groups, respectively; only one event (hepatic dysfunc-
tion) in the TAS-118 group was judged to be treatment
related.
Median relative dose intensity was 90.7% and 94.0%
in the TAS-118 and S-1 groups, respectively. No dif-
ferences were observed between the countries
(Supplementary Table S7).4. Discussion
This study was one of the largest phase 3 studies of
patients with gemcitabine-refractory advanced pancre-
atic cancer. TAS-118 did not significantly improve OS,
but modestly improved PFS. There are some possible
reasons for not meeting the primary objective.
OS in both treatment groups was longer than ex-
pected, decreasing the statistical power. Median OS in
this study was longer than reported in other studies of
second-line chemotherapy [5,6], including our previous
phase 2 study [12]. Baseline characteristics in this study
were better than those in other studies. For example, the
eligibility criteria of this study required serum albumin
3.5 g/dL compared to 3.0 g/dL in the NAPOLI-1
study and our previous phase 2 study [6,12]. Also,
measurable lesions were required in our previous phase
2 study, but not in this study. Only one prior chemo-
therapy was allowed in this study, while over 30% of
patients received two or more lines of prior chemo-
therapies in NAPOLI-1. These differences may partially
explain the longer OS in this study. Post-study treatment
might contribute to prolonged OS. Approximately 60%
of patients received post-study treatment, compared
with <40% in NAPOLI-1 [6]. Furthermore, approxi-
mately 10% of patients were treated with FOLFIR-
INOX and gemcitabine plus nab-paclitaxel. Hence, the
significant prolongation of PFS with TAS-118 might not
be translated into OS improvement.
There was a substantial interaction in the counties
regarding the efficacy of TAS-118 and S-1 on OS; sur-
vival benefit of TAS-118 was suggested in the Japanese
patients but not in the Korean patients. OS appeared to
be shorter in the Korean patients than the Japanese
patients as we expected when designed this study
(Fig. 4A). Korean patients showed worse PS and higher
CRP levels than Japanese patients at baseline. Treat-
ment history with gemcitabine differed slightly between
the two countries; more Japanese patients received
treatment for initially unresectable disease, more
Fig. 2. KaplaneMeier curve of (A) overall survival and (B) progression-free survival. CI, confidence interval; HR, hazard ratio.
T. Ioka et al. / European Journal of Cancer 106 (2019) 78e88 83Korean patients received adjuvant chemotherapy after
pancreatic resection and more Korean patients received
combination therapy as first-line treatment. These dif-
ferences would be associated with shorter survival in
Korean patients, and some factors might generate an
interaction of efficacy in the two countries.
Pancreatic resection history is known to be a prog-
nostic factor [14]. Patients with initially unresectable
disease generally have larger tumour burdens than those
with recurrent disease. Indeed, OS was longer in patientswith prior pancreatic resection than those with initially
unresectable patients (Fig. 4b). This trend was observed
in both countries. The subgroup of Japanese patients
without pancreatic resection showed significant OS
improvement with TAS-118 compared to S-1, whereas
the subgroup with pancreatic resection showed no
improvement in OS with TAS-118 (Supplementary
Fig. S1a). There was no difference of OS between
TAS-118 and S-1 in the Korean patients without
pancreatic resection, while OS in TAS-118 was rather
Fig. 3. Forest plot of (A) overall survival and (B) progression-free survival. CI, confidence interval; ECOG, Eastern Cooperative Oncology
Group; GEM, gemcitabine; HbA1c, glycated hemoglobin.
T. Ioka et al. / European Journal of Cancer 106 (2019) 78e8884worse in those with pancreatic resection (Supplementary
Fig. S1b). NAPOLI-1 also reported that OS in the
experimental nanoliposomal irinotecan arm was shorter
than in the control arm (HR Z 1.23) in patients with
pancreatic resection [6]. In our study, half of the Korean
patients had undergone pancreatic resection, compared
to only 23% of the Japanese patients. This might ac-
count for efficacy differences between the two countries,
although persuasive explanation is difficult why such
efficacy differences occurred between patients with and
without pancreatic resection. Considering such a similar
result in different trials, intensive chemotherapy may
have adverse impacts on survival of patients with
pancreatic resection. In future study designs, pancreaticresection history should be considered as an important
factor that influences treatment efficacy.
The Z score analysis was preplanned to explore the
reasons for regional differences in the efficacy of TAS-
118 versus S-1. Z scores of Japanese patients with
TAS-118 showed longer OS and PFS in all subgroups
classified by combination of the prespecified factors, and
Korean patients showed even shorter OS and PFS in all
subgroups. Thus, there might be other factors than
those expected affecting the efficacy of TAS-118.
The safety profiles of TAS-118 and S-1 were consis-
tent with previous reports of S-1/LV or S-1 alone
[10e12], and both treatments were well tolerated. The
toxicities of TAS-118 were well managed by appropriate
Fig. 3. (continued).
T. Ioka et al. / European Journal of Cancer 106 (2019) 78e88 85dose reduction. Given the increasing number of patients
who receive intensive first-line treatment with nab-
paclitaxel- or oxaliplatin-containing regimens, a less
toxic regimen with substantial efficacy can be an option
for second-line treatment.
In conclusion, despite the modestly prolonged PFS
obtained with TAS-118, OS was not improved. The
subgroup analyses suggested that TAS-118 might be
more effective than S-1 in some populations. Further
studies are warranted to determine optimal use of TAS-
118.
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(0.70–1.04) P=0.129S-1 209 193 7.4
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TAS-118 85 74 8.7 1.51
(1.07–2.14) P=0.050S-1 81 61 9.4
TAS-118, pancreatic resection: no
S-1, pancreatic resection: no
TAS-118, pancreatic resection: yes
S-1, pancreatic resection: yes
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Fig. 4. KaplaneMeier curves of overall survival by (A) country and (B) history of pancreatic resection. CI, confidence interval; HR,
hazard ratio.
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Table 2
Commonly reported adverse events (10% of patients in either treatment group).
Adverse events TAS-118 (n Z 300) S-1 (n Z 301)
Any grade Grade 3 Any grade Grade 3
Any event 300 (100.0%) 188 (62.7%) 293 (97.3%) 161 (53.5%)
Haematologic
Anaemia 53 (17.7%) 18 (6.0%) 57 (18.9%) 26 (8.6%)
Neutropaenia 35 (11.7%) 5 (1.7%) 35 (11.6%) 10 (3.3%)
Leucocytopenia 35 (11.7%) 4 (1.3%) 38 (12.6%) 3 (1.0%)
Thrombocytopenia 33 (11.0%) 5 (1.7%) 46 (15.3%) 5 (1.7%)
Non-haematologic
Decreased appetite 174 (58.0%) 28 (9.3%) 165 (54.8%) 21 (7.0%)
Stomatitis 151 (50.3%) 20 (6.7%) 84 (27.9%) 2 (0.7%)
Diarrhoea 146 (48.7%) 22 (7.3%) 128 (42.5%) 24 (8.0%)
Skin hyperpigmentation 122 (40.7%) 0 (0.0%) 85 (28.2%) 0 (0.0%)
Nausea 120 (40.0%) 5 (1.7%) 122 (40.5%) 2 (0.7%)
Malaise 101 (33.7%) 4 (1.3%) 85 (28.2%) 1 (0.3%)
Palmar-plantar erythrodysesthesia syndrome 72 (24.0%) 5 (1.7%) 35 (11.6%) 0 (0.0%)
Vomiting 71 (23.7%) 6 (2.0%) 70 (23.3%) 2 (0.7%)
Lacrimation increased 65 (21.7%) 1 (0.3%) 47 (15.6%) 1 (0.3%)
Dysgeusia 64 (21.3%) 0 (0.0%) 50 (16.6%) 0 (0.0%)
Fatigue 55 (18.3%) 3 (1.0%) 53 (17.6%) 2 (0.7%)
Pyrexia 51 (17.0%) 1 (0.3%) 52 (17.3%) 0 (0.0%)
Weight decreased 49 (16.3%) 6 (2.0%) 38 (12.6%) 3 (1.0%)
Constipation 41 (13.7%) 4 (1.3%) 42 (14.0%) 3 (1.0%)
Rash 37 (12.3%) 2 (0.7%) 21 (7.0%) 1 (0.3%)
Epistaxis 35 (11.7%) 0 (0.0%) 15 (5.0%) 0 (0.0%)
Hypoalbuminaemia 32 (10.7%) 10 (3.3%) 33 (11.0%) 5 (1.7%)
Abdominal pain 31 (10.3%) 7 (2.3%) 35 (11.6%) 4 (1.3%)
Oedema peripheral 31 (10.3%) 0 (0.0%) 20 (6.6%) 0 (0.0%)
Dry skin 31 (10.3%) 0 (0.0%) 18 (6.0%) 0 (0.0%)
Insomnia 30 (10.0%) 0 (0.0%) 20 (6.6%) 0 (0.0%)
Analysis set: safety population.
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